| adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma |
NCT03474289: Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors |
|
|
| Unknown status | 1 | 134 | RoW | SHR-1316, HTI-1088 | Jiangsu HengRui Medicine Co., Ltd. | Tumor | 01/19 | 10/19 | | |
NCT03133247: A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients |
|
|
| Completed | 1 | 37 | RoW | SHR-1316, HTI-1088 | Atridia Pty Ltd. | Advanced Solid Tumors | 04/19 | 07/19 | | |
NCT04041011: A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients |
|
|
| Completed | 1 | 23 | RoW | 1.Experimental: A (Part 1): Fluzoparib and SHR -1316, 2.Experimental: B (Part 1): Fluzoparib and SHR -1316, 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion | Jiangsu HengRui Medicine Co., Ltd. | Small Cell Lung Cancer | 04/21 | 04/21 | | |
NCT04979390: Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors |
|
|
| Not yet recruiting | 1 | 15 | NA | SHR-1316 | Jiangsu HengRui Medicine Co., Ltd. | Tumor | 02/22 | 07/22 | | |
NCT03995472: A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors |
|
|
| Completed | 1 | 14 | RoW | SHR-1501, SHR-1316 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Malignancies | 01/23 | 01/23 | | |
NCT05198817: A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients |
|
|
| Enrolling by invitation | 1 | 240 | RoW | SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Malignant Tumors | 01/23 | 06/23 | | |
NCT06181032: A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies |
|
|
| Recruiting | 1 | 35 | RoW | Adebrelimab, SHR-1316, Apatinib, Gemcitabine, Cisplatin | First Affiliated Hospital of Fujian Medical University | Biliary Tract Malignancies | 02/29 | 02/29 | | |
NCT06225921: Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas |
|
|
| Recruiting | 1 | 6 | RoW | Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg | West China Hospital | Esophageal Squamous Cell Carcinoma | 01/25 | 01/25 | | |
NCT06156267: Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino |
|
|
| Not yet recruiting | 1 | 30 | RoW | Adebrelimab, mRNA tumor vaccines | Fudan University, Shanghai Regenelead Therapies Co., Ltd. | Pancreatic Cancer | 04/26 | 03/27 | | |
NCT06336707: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 1048 | NA | HS-20089, Adebrelimab, Bevacizumab, Cisplatin / carboplatin | Hansoh BioMedical R&D Company | Advanced Solid Tumors | 04/26 | 04/28 | | |
NCT06332170: ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 610 | NA | HS-20093, Adebrelimab, Cisplatin/ Carboplatin, Cetuximab, Enzalutamide | Hansoh BioMedical R&D Company | Advanced Solid Tumor | 05/26 | 05/28 | | |
| Recruiting | 1 | 924 | RoW | SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab | Shanghai Hengrui Pharmaceutical Co., Ltd. | Cldn18.2-positive Advanced Solid Tumor | 12/27 | 12/28 | | |
NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 345 | RoW | HRS2300, HRS2300、 SHR-1316, HRS2300、SHR-1701, HRS2300、trametinib, HRS2300、Almonertinib | Jiangsu HengRui Medicine Co., Ltd. | Advanced Malignancies | 01/25 | 03/25 | | |
MA-SCLC-I-007, ChiCTR2300074036: Safety and efficacy of Adebrelimab Injection combined with Linperlisid Tablets in the treatment of limited stage SCLC after radiotherapy and chemotherapy: Phase I clinical study |
|
|
| Recruiting | 1 | 32 | | Adelbilizumab combined with linprixel for treatment | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Jiangsu Hengrui Pharmaceuticals Co., Ltd | Limited stage Small Cell Lung Cancer | | | | |
NCT05082545: Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors |
|
|
| Completed | 1 | 19 | RoW | SHR-2002 and SHR-1316 | Atridia Pty Ltd. | Advanced Malignant Tumors | 07/23 | 02/24 | | |
NCT05942378: A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 30 | RoW | HRXG-K-1939, HRXG-K-1939 is a mRNA cancer vaccines, Adebrelimab | Fudan University | Advanced Solid Tumors | 09/25 | 12/25 | | |
